Tagged with trials

Italy Italy is a key destination for global clinical trial programs with EUR 700 million invested in 2020 alone according to national industry association Farmindustria, bringing access to medicines, knowledge, skills, and economic benefits. Here, Italy country managers from some of the world’s leading pharma companies weigh in on the pros…

Spain Soon after reaching its 60th anniversary, in 2015, the largest hospital in Catalonia and a group of sister institutions began working on the creation of a new type of campus. The idea was to follow the footsteps of world-leading healthcare hubs.   The idea of strengthening the cluster was an…

Global Writing in the February edition of DIA’s Global Forum magazine, Candice Del Rio of Curavit Clinical Research examines the applicability of decentralised clinical trials in oncology research, and their positive impact on both decreasing patient dropout rates and increasing patient engagement. Oncology represents the largest research area globally, with 6.5 percent…

Spain Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19 treatment, and the reimbursement challenges faced by rare disease players in Spain. Moreover, De Mora highlights Sobi’s vast clinical trials…

Spain Lilly’s Nabil Daoud highlights the evolution in the firm’s Spanish manufacturing and R&D footprint in recent years, discussed launch plans for its next-generation diabetes and obesity treatments, and outlines some of the key trends currently impacting healthcare in Spain.   Four years ago, a molecule discovered and designed by scientists…

Italy   In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s third largest in Europe and sixth largest globally. Giese also touches on ensuring the affiliate’s product launch readiness, consistently increasing…

Italy Lilly’s president and general manager for its Italy hub, Huzur Devletsah, explains the company’s broad footprint in the country – where Lilly maintains a large manufacturing site that produces over half of their global insulin output and from which it oversees 28 countries. In addition, she comments on the upcoming…

Saudi Arabia The general manager for Recordati Rare Diseases in MENA, Tony Zbeidy, explains why awareness of rare disorders has vastly improved in the region, which has one of the largest incidence rates in the world, the particular importance of the Saudi Arabian market to Recordati, the need for a more collaborative…

Spain According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends include the fact that generics penetration in Spain has remained at a constant level for almost seven years and private…

Spain A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona. The region boasts a strong scientific output by European standards, is the birthplace of many of Spain’s pharma success stories,…

Denmark Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international collaboration, not least with neighbouring Sweden (population 10.4 million), has the potential to greatly increase the pool from which trial…

Australia Australia’s international outlook, strong science base, multi-ethnic English-speaking population and high educational and regulatory standards make it an attractive location to undertake clinical trials for medicines and vaccines. These fundamentals were foregrounded during the COVID-19 pandemic, when Australia was able to pivot quickly and develop capabilities in technology and tele-monitoring…